CHRO vs. BCDA, ONVO, IKT, GENE, NSTGQ, SRNE, COEP, PALI, CELZ, and TTNP
Should you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include BioCardia (BCDA), Organovo (ONVO), Inhibikase Therapeutics (IKT), Genetic Technologies (GENE), NanoString Technologies (NSTGQ), Sorrento Therapeutics (SRNE), Coeptis Therapeutics (COEP), Palisade Bio (PALI), Creative Medical Technology (CELZ), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.
Chromocell Therapeutics (NYSE:CHRO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Chromocell Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -2,425.79%. Chromocell Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.
78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Chromocell Therapeutics has higher earnings, but lower revenue than BioCardia.
BioCardia received 10 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
BioCardia has a consensus target price of $4.00, indicating a potential upside of 910.36%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Chromocell Therapeutics.
In the previous week, BioCardia had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for BioCardia and 0 mentions for Chromocell Therapeutics. BioCardia's average media sentiment score of 1.25 beat Chromocell Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.
Summary
BioCardia beats Chromocell Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Chromocell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chromocell Therapeutics Competitors List
Related Companies and Tools
